Table 2.

Simulated Steady State Dose Exposure Summary

Indication	Dose mg/kg	Interval (hours)	BGA A (wks)	PNA A (days)	[Fluc] B (µg/ml)	AUC B (mg*hr/L)	AUC C 10th %	AUC C 90th %	%Time>MIC E (median)
Treatment IC	12	Q24	23–29	7–80	23 (11) 22	720 (247) 680	430	1030	NA
	12	Q24	30–40	1–80	15 (7.4) 14	540 (190) 520	340	790	NA
Early Prevention	3	Q Tue/Fri	23–29	1–42	2.3 (1.3) 2.1	53 (28) 50	20	90	58% T>MIC2 3 % T>MIC4
	6	Q Tue/Fri	23–29	1–42	4.2 (2.6) 4.0	107 (55) 101	40	180	93% T>MIC2 47% T>MIC4
Late Prevention	3	Q24	23–29	7–42	6.9 (3.1) 6.5	163 (60) 156	93	243	85% T>MIC4
	6	Q72	23–29	7–42	5.0 (2.7) 4.4	112 (59) 108	43	190	57% T>MIC4
	6	Q48	23–29	42–80	6.0 (3.2) 5.5	135 (64) 131	59	218	67% T>MIC4
	6	Q48	30–40	1–42	5.5 (3.0) 5.0	128 (57) 122	60	205	63% T>MIC4

IC, invasive candidiasis; wk, weeks; BGA, gestational age at birth; PNA postnatal age; [Fluc] plasma concentration of fluconazole;

^Arange of infant characteristics

^Bmean (standard deviation) median

^Cpercentile of simulation

^ETypical MIC for Candida species in NICU, MIC₉₀ ≤ 4 µg/ml.